|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Veterinary Vaccines
|
Feb 2011 |
£2,845 |
100% |
|
Hepatitis C Virus And Therapeutics
|
Apr 2009 |
£2,500 |
91% |
Hepatitis C Virus and Therapeutics
A Global Update of Market Trends & Opportunities
|
Nov 2009 |
£1,895 |
90% |
Bayer AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
85% |
MorphoSys AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
80% |
Prospects for Pharma Mergers, Acquisitions and Alliances
2010-2020
|
Jul 2010 |
£1,499 |
79% |
|
Chronic Obstructive Pulmonary Disease
|
Feb 2010 |
£2,180 |
79% |
Veterinary Vaccines
A World Market Analysis
|
Nov 2009 |
£1,895 |
78% |
Celentyx Ltd. – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
77% |
Prostate Cancer Therapeutics
A Global Market Perspective
|
Nov 2009 |
£1,895 |
77% |
|
Rheumatoid Arthritis Therapeutics
|
Feb 2010 |
£2,500 |
76% |
Valeant Pharmaceuticals International, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
75% |
Egalet a/s – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
75% |
ViroPharma Incorporated – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
74% |
XOMA Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
72% |
|
Monoclonal Antibody Based Products
|
Oct 2008 |
£2,500 |
70% |
Commercial Insight: Antipsychotics
Revenues of depots and new agents will partially offset generic erosion
|
Oct 2009 |
£9,615 |
70% |
Lupin Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
70% |
AVEO Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
69% |
Animal Pharm's Top Tier Companies
2007 Edition
|
Jan 2007 |
£895 |
68% |
|
Prostate Cancer Therapeutics
|
Apr 2009 |
£2,500 |
67% |
Cancer Therapies
Global Market Opportunities
|
Nov 2009 |
£1,895 |
66% |
Analysis of Oncology Deals
Trends in Deal Structures and Valuations
|
Dec 2009 |
£2,243 |
66% |
Galapagos NV – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
66% |
Mylan Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
62% |
|
Contraceptives
|
Oct 2010 |
£2,845 |
62% |
Delivering New Biopharmaceutical Therapies
Challenges & Opportunities
|
Jan 2009 |
£945 |
61% |
Endotis Pharma – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
60% |
Key Companies: HIV
Companies co-operate and co-formulate to stay competitive in a tight HIV market
|
Jun 2011 |
£2,405 |
60% |
|
Medicated Skin Care Products
|
Jan 2011 |
£2,845 |
60% |
